Aurobindo Pharma unit ends vaccine license agreement

Aurobindo Pharma announced today that its wholly-owned step-down subsidiary, Auro Vaccines Private Limited, has terminated its License Agreement with Hilleman Laboratories Singapore Pte, Limited, effective March 5, 2025. The agreement, initially entered on September 27, 2023, pertained to the development, manufacturing, and commercialization of a pentavalent vaccine candidate intended for use in children's vaccination. Aurobindo Pharma clarified that Auro Vaccines Private Limited is not considered a material subsidiary. The company stated that the termination of this early-stage vaccine asset license is not expected to have a significant impact on the company's operations or financials. Aurobindo Pharma will keep exchanges informed of any significant impacts in the future. The company is disclosing this information in accordance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.